By Reuters staff
(Reuters) – University students in the United States, vaccinated with Moderna Inc’s COVID-19 vaccine, will be part of a new study to test its effectiveness in slowing the spread of the virus, the COVID-19 Prevention Network said on Friday. .
The trial, supported by the National Institutes of Health (NIH), is designed to determine whether the vaccine, mRNA-1273, can prevent coronavirus infection, limit the virus in the nose, and reduce transmission from vaccinated people to their contacts. close.
The Prevent COVID U study, funded by the National Institute of Allergy and Infectious Diseases (NIAID), will monitor about 12,000 young adults at 20 universities over a five-month period.
Half of the students will be vaccinated at the time of enrollment, while the other half will receive the vaccine four months late, according to the network, formed by the NIAID to conduct vaccine and antibody studies for the new coronavirus.
The students, as well as the 25,000 people named by them as “close contacts,” will complete questionnaires, take nasal swab samples and provide blood samples over a designated period, allowing study researchers to measure the spread of the virus.
“Our hope is that we demonstrate that COVID-19 vaccines prevent people from getting infected with the coronavirus in the first place and stop transmission to others,” said Dr. Larry Corey, principal investigator for the network’s operations program.